v3.25.2
Capital Stock (Tables)
 12 Months Ended
Mar. 31, 2025
Equity [Abstract]  
Schedule of Common Stock Warrants Outstanding
At March 31, 2025, the following common stock warrants were outstanding:
Number of common shares
underlying warrants		Exercise price
per share		Expiration
date
12,352$21.9007/25/2025
2,788,620$0.001N/A
9,294,022$5.380(a)
11,265,086$8.87710/4/2028
(a) The warrants will expire 60 days after the later of (i) the date on which the Company first publicly discloses, whether by press release or Form 8-K filing, the top-line data for its PALISADE-3 Phase 3 clinical trial of fasedienol for the acute treatment of anxiety in adults with SAD
and (ii) the date on which the Company first publicly discloses, whether by press release or Form 8-K filing, the top-line data for its PALISADE-4 Phase 3 clinical trial of fasedienol for the acute treatment of anxiety in adults with SAD.
Schedule of Common Stock Reserved for Future Issuance
We had the following shares of common stock reserved for future issuance:
As of March 31,
20252024
Issuance of common stock upon exercise of outstanding stock options under the Amended and Restated 2016 Stock Incentive Plan and the Amended and Restated 2019 Omnibus Equity Incentive Plan3,239,642 815,357 
Issuance of common stock upon exercise of outstanding warrants43,952,783 44,741,142 
Equity awards available under the Amended and Restated 2019 Omnibus Equity Incentive Plan2,042,153 466,438 
Shares available for issuance under the 2019 Employee Stock Purchase Plan911,342 19,480 
Shares reserved under the Sales Agreement27,951,416 29,060,003 
78,097,336 75,102,420